首页> 美国卫生研究院文献>Springer Open Choice >Liqui-Pellet: the Emerging Next-Generation Oral Dosage Form Which Stems from Liquisolid Concept in Combination with Pelletization Technology
【2h】

Liqui-Pellet: the Emerging Next-Generation Oral Dosage Form Which Stems from Liquisolid Concept in Combination with Pelletization Technology

机译:Liqui-Pellet:由Liquisolid概念与造粒技术相结合的新兴下一代口服剂型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In spite of the major advantages that the liquisolid technology offers, particularly in tackling poor bioavailability of poorly water-soluble drugs (i.e., BCS Class II drugs), there are a few critical drawbacks. The inability of a high liquid load factor, poor flowability, poor compactibility, and an inability to produce a high dose dosage form of a reasonable size for swallowing are major hurdles, hampering this technology from being commercially feasible. An attempt was therefore made to overcome these drawbacks whilst maintaining the liquisolid inherent advantages. This resulted in the emerging next generation of oral dosage forms called the liqui-pellet. All formulations were incorporated into capsules as the final product. Solubility studies of naproxen were conducted in different liquid vehicles, namely polyethylene glycol 200, propylene glycol, Tween 80, Labrafil, Labrasol, and Kolliphor EL. The scanning electron microscopy studies indicated that the liquid vehicle tends to reduce the surface roughness of the pellet. X-ray powder diffraction (XRPD) indicated no significant differences in the crystalline structure or amorphous content between the physical mixture and the liqui-pellet formulation. This was due to the presence of a high concentration of amorphous Avicel in the formulation which overshadowed the crystalline structure of naproxen in the physical mixtures. Flowability and dissolution tests confirmed that this next-generation oral dosage form has excellent flowability, whilst maintaining the typical liquisolid enhanced drug release performance in comparison to its physical mixture counterpart. The liqui-pellet also had a high liquid load factor of 1, where ~ 29% of the total mass was the liquid vehicle. This shows that a high liquid load factor can be achieved in a liqui-pellet without compromising flowability. Overall, the results showed that the poor flowability of a liquisolid formulation could be overcomed with the liqui-pellet, which is believed to be a major advancement into the commercial feasibility of the liquisolid concept.
机译:尽管液固技术具有许多主要优点,尤其是在解决水溶性差的药物(即BCS II类药物)的生物利用度差的问题上,但仍有一些关键缺点。高液体负荷因子的不能,流动性差,可压实性差以及不能产生用于吞咽的合理尺寸的高剂量剂型是主要障碍,阻碍了该技术的商业可行性。因此,试图在保持液态固体固有优点的同时克服这些缺点。这导致了新一代的口服剂型的出现,即液体小丸。将所有制剂作为最终产物掺入胶囊中。萘普生的溶解度研究是在不同的液体媒介物中进行的,即聚乙二醇200,丙二醇,吐温80,Labrafil,Labrasol和Kolliphor EL。扫描电子显微镜研究表明,液体载体趋于降低粒料的表面粗糙度。 X射线粉末衍射(XRPD)表明物理混合物和液体-小球制剂之间的晶体结构或无定形含量没有显着差异。这是由于在制剂中存在高浓度的无定形阿维塞尔,这掩盖了物理混合物中萘普生的晶体结构。流动性和溶出度测试证实,这种下一代口服剂型具有出色的流动性,并且与物理混合物相比,在保持典型的液固增强药物释放性能的同时。液体小丸的液体负载系数也很高,为1,其中液体载体占总质量的〜vehicle29%。这表明可以在不损害流动性的情况下在液体颗粒中获得高的液体负载率。总体而言,结果表明,可以通过液粒克服液状固体制剂的差的流动性,这被认为是液状固体概念的商业可行性的重大进步。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号